09:00-10:00 |
Morning Plenary Session |
Plenary Hall |
| 09:00-09:15 |
Dr. Aharon Schwartz
Conference Chairperson
Conference Official Opening
Mr. Ehud Olmert
Vice Prime Minister & Minister ofIndustry, Trade and Labor
Welcome to Conference Participants |
|
| 09:15-10:00 |
Chairperson: Prof. Eithan Galun
Hadassah University Hospital, Israel
Keynote Speaker: Dr. William J. Rutter
Chairman and CEO Synergenics
Synergenics Cooperative Biotech Ventures
|
|
10:00-11:30 |
The MetabolicDiseases Session |
Plenary Hall |
| 10:00-10:30 | Prof. Barbara Corkey
Boston University School of Medicine, USA
Gaps in Understanding the Pathophysiology of Diabetes and Obesity
|
|
| 10:30-11:00 |
Prof. Joseph Schlessinger
Yale University School of Medicine, USA
Cell Signalling by Receptor Tyrosine Kinases: From the Bench to the Bedside
|
|
| 11:00-11:30 |
Prof. Lutz Heinemann
Profil Institute for Metabolic Research, Germany
The Role of Artificial Pancreas in the Cure of Diabetes
|
|
| 11:30-12:00 |
COFFEE BREAK |
|
12:00-13:15 |
Metabolic Diseases - Company Presentations - Parallel Sessions |
|
| |
| HALL A |
HALL B |
HALL C |
Chairperson
Prof. A. Ludomirski |
Chairperson
Dr. N. Darvish |
Chairperson
Dr. R. Bendori |
D. Aviezer
PROTALIX BIOTHERAPEUTICS LTD
Plant Cell Cultures Expressing Enzyme Therapeutics for Gaucher’s Disease
|
I. Harosh
OBE THERAPY
“Lean Genes” as Targets for the Treatment Of Obesity
|
S. Marcus
DEVELOGEN AG
Develogen-European Leader in Metabolic Disorders
|
Y. Levin
NanoPass TECHNOLOGIES LTD
MicroPyramid™ Drug Delivery Solutions
|
R. Oren
TEL AVIV SOURASKY MEDICAL CENTRE
Role Of Cyp2d6 Polymorphism in Predicting Liver Fibrosis Progression Rate in Caucasian Patients with Chronic Hepatitis C
|
L.D. Ma’ayan
ORSENSE LTD
The use of Non Invasive Blood Glucose Monitoring in Diabetes
|
B. Pesach
GLUCON
Continuous, Non-Invasive Blood Glucose Monitor based on Photoacoustic Technology
|
K. Shetty
UNIVERSITY OF MASSACHUSETTS
Biosynthesis of Dietary Phenolic Antioxidants for Metabolic Disorders
|
G. Levin
TRANSPHARMA-MEDICAL LTD
Transdermal Delivery of Hgh and Insulin
|
Y. Zicherman
ADM LTD
Colonic Transit Time is Reduced and Constipation is Relieved when Specific Mode of Movement is Applied on the Abdomen
|
M. Baru
OMRI LABORATORIES LTD
Prolongation of Protein Half-Life and Enhancement of Biological Activity by Formulation with Pegylated Lipsomes Shows Important Clinical Benefits
|
S. Ferber
THE ENDOCRINE INSTITUTE
Cell-Replacement Therapy for Diabetes; Generating Functional Insulin Producing Tissue from Adult Human Liver Cells
|
O. Zik
QUANTOMIX LTD
Imaging Lipid Accumulation By WETSEM™ - A New Marker For Metabolic Diseases
|
C. Schneider
BETA-02 TECHNOLOGIES LTD
Innovative Method for the Treatment of Diabetes Type I Patients
|
N. Barak
OBECURE
The Effect of Betahistine on Weight, Appetite and Caloric Intake
|
|
|
| 13:00-14:00 |
LUNCH BREAK |
|
14:00-14:30 |
Afternoon Plenary Session
Chairperson: Dr. Rafi Hofstein
Hadasit Ltd
|
Plenary Hall |
| 14:00-14:30 |
Dr. Eli Opper
Chief Scientist, Ministry of Industry, Trade & Labor
Advancing Life Science Technologies
|
|
14:30-16:00 |
The Central Nervous System Diseases Session |
Plenary Hall |
| 14:30-15:00 |
Dr. Garnette Sutherland
Foothills Medical Center, Canada
Project Neuroarm-Advancing Surgical Robotics
|
|
| 15:00-15:30 |
Dr. Manfred Windisch
JSW, Cato Research, Austria
Therapy of Alzheimer’s Disease-Can We Stop Progression?
|
|
| 15:30-16:00 |
Dr. Gideon Dreyfuss
University of Pennsylvania School of Medicine, USA
The Survival of Motor Neurons Complex, A Molecular Assembly Machine
|
|
| 16:00-16:30 |
COFFEE BREAK
|
|
16:30-17:30 |
CNS Diseases Session - Company Presentations - Parallel Sessions |
|
| |
| HALL A |
HALL B |
HALL C |
Session Chairperson
Mr. Z. Weiss |
Session Chairperson
Dr. A. Waks |
Session Chairperson
Prof. V.Teichberg |
N. Nimrodi
PRONEURON BIOTECHNOLOGIES INC
Advances In the Treatment of Spinal Cord Injury and other CNS Disorders
|
I. Gozes
ALLON THERAPEUTICS INC
Nap (Al-108) A Novel Drug Candidate for the Treatment of Alzheimer’s Disease.
|
S. Halachmi
BIOLINERX
Bl-1020, A Novel Gaba-Targeting Antipsychotic with Improved Therapeutic Profile
|
D. Atlas
INSTITUTE OF LIFE SCIENCES
NOVIA LTD
Ad-4, A Potential Drug for Treating Neurodegeneration
|
Y. Mardor
SHEBA MEDICAL CENTER
Enhanced Efficacy and Mr Imaging of a Novel Brain-Tumor Treatment, Convection Enhanced Drug Delivery (Ced)
|
S. Kindler
PHARMOS LTD
Pharmos - Synthetic Cannabinoids as Novel Therapeutics
|
Y. Beck
BRAINSTORM CELL THERAPEUTICS
Brainstorm Cell Therapeutics-from Bone Marrow to Brain Cells
|
J. Aldag
EVOTEC OAI AG
Evotec-Building A Sustainable CNS Portfolio
|
A. Hoffman
INTEC PHARMA LTD
An “Accordion Pill” for Levodopa Controlled Release in the Stomach
|
I. Angel
D-PHARM LTD
Update on Dp-B99 a Membrane Active Chelator in Phase IIb Clinical Trials for Acute Stroke and Dp-Vpa a Valproic Acid Prodrug in Phase II For Epilepsy
|
O. Becker
PREDIX PHARMACEUTICALS LTD
Discovery and Development of Predix’s Novel Anxiety and Novel Alzheimer’s Drugs
|
V. Teichberg
WEIZMANN INSTITUTE
Treating Acute Brain Neurodegenerative Diseases with Blood Glutamate Scavengers
|
L. Carmon
ESTER NEUROSCIENCES |
D. Yarnitsky
BRAINSGATE
Breakthrough Approach to CNS Therapy
|
ALPHA OMEGA |
|
|
|
|
|
|
![BIO-TECH ISRAEL 2005: The Israel Biomedical Technologies CONFERENCE AND EXHIBITION [Tel Aviv, Israel, May 24-26, 2005]](images/bioLogo.gif)
![BIO-TECH ISRAEL 2005: The Israel Biomedical Technologies CONFERENCE AND EXHIBITION [Tel Aviv, Israel, May 24-26, 2005]](images/forTop.gif)
